Super Human Growth Hormone

enjoy your life with super hgh

Archive for November 11th, 2008

If recombinant canadian human growth hormone (rhGH) is started early in the course of glucocorticoid treatment of children with juvenile idiopathic arthritis (JIA), it preserves “normal growth velocity and height,” French researchers report in the July issue of the Journal of Clinical Endocrinology and Metabolism.

The investigators randomized 30 children with severe JIA who had been on glucocorticoid treatment for 12 to 15 months to rhGH 0.46 mg/kg per week via daily subcutaneous injections, or to no Human Growth Hormone treatment, for 3 years.

There was a mean height increase in the HGH group, with a positive change in the standard deviation score (SDS) of 0.37, while there was a drop in SDS of 0.96 in the control group, report Dr. Dominque Simon of the Robert Debre Teaching Hospital and colleagues elsewhere in Paris.

Mean height velocity returned to normal in Human Growth Hormone  - treated children during the first year and remained normal for the duration of the study. Height velocity was below normal in the children not given Human Growth Hormone .

There was a mean lean mass increase of 7.3 kg with Human Growth Hormone treatment compared with 4.4 kg with no treatment.

“Treatment with Human Growth Hormone did not seem to improve bone health in our prepubertal JIA children,” Dr. Simon and colleagues found. Bone mineralization and fat mass were similar in the two groups.

Buy hgh

Fasting glycemia was unchanged in either group. However, the investigators call attention to the finding that fasting serum insulin increased 5.2 mIU/liter in Human Growth Hormone  - treated children and dropped 2.3 mIU/liter in untreated controls.

“JIA children treated with Human Growth Hormone may be at increased risk for alterations in carbohydrate metabolism, because Human Growth Hormone may add to the effects of chronic inflammation and high-dose glucocorticoid therapy in inducing insulin resistance,” the team cautions.

Summing up, they conclude that “hgh growth hormone therapy in patients with JIA, when started before the onset of growth retardation, normalized prepubertal growth, thus preserving height potential.”

Tolerance and safety were acceptable, although the data indicated a need for closely monitoring the carbohydrate metabolism. In addition, our results on tolerance and safety should be interpreted with caution, given the short follow-up and small number of patients.